Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254070, C514S319000, C544S370000, C546S205000
Reexamination Certificate
active
07977339
ABSTRACT:
Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.
REFERENCES:
patent: 6960601 (2005-11-01), Smith et al.
patent: 7795265 (2010-09-01), Berger et al.
patent: 2004/0063691 (2004-04-01), Smith et al.
patent: 2005/0054679 (2005-03-01), Kruse et al.
patent: 2005/0124660 (2005-06-01), Antel et al.
patent: 2005/0197377 (2005-09-01), Breitenbucher et al.
patent: 2005/0256167 (2005-11-01), Smith et al.
patent: 2007/0066644 (2007-03-01), de Lera Ruiz et al.
patent: 2007/0167435 (2007-07-01), Mutahi et al.
patent: 0646648 (1995-04-01), None
patent: 01/85723 (2001-11-01), None
patent: 02/055495 (2002-07-01), None
patent: 03/007887 (2003-01-01), None
patent: 03/040107 (2003-05-01), None
patent: 03/063781 (2003-08-01), None
patent: 2004/094407 (2004-11-01), None
patent: 2005/009974 (2005-02-01), None
patent: 2005/040130 (2005-05-01), None
patent: 2005/063716 (2005-07-01), None
patent: 2005/095354 (2005-10-01), None
patent: 2006/033891 (2006-03-01), None
patent: 2007/120688 (2007-10-01), None
patent: 2007/120718 (2007-10-01), None
Little, “Role of cholecystokinin in appetiite control and body weight regulation”, Obesity Rev. (2005), vol. 6, pp. 297-306.
Moran, “Gastrointestinal satiety signals”, Am. J. Physiol.: Gastrointest. Liver Physiol. (2004), vol. 286, pp. G183-G188.
Lange, “Bioisosteric replacements of the pyrazole moiety of rimonabant . . . ”, J. Med. Chem. (2005), vol. 48, pp. 1823-1838.
Asproni, “Synthesis, structure—activity relationships at the GABAA receptor in rat brain, . . . ”, J. Med. Chem. (2005), vol. 48, pp. 2638-2645.
Khanna, “1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active . . . ”, J. Med. Chem. (1997), vol. 40, pp. 1634-1647.
Khanna, “Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles . . . ”, J. Med. Chem. (2000), vol. 43, pp. 3168-3185.
Asproni, “Synthesis and pharmacological evaluation of 1-[(1,2-Diphenyl-1H-4-imidazolyl) . . . ”, J. Med. Chem. (2002), vol. 45, pp. 4655-4668.
Szewczyk, “CCK1R agonists: a promising target for the pharmacological . . . ”, Curr. Topics in Med. Chem. (2003), vol. 3, pp. 837-854.
Varga, “Involvement of endogenous CCK and CCK1 receptors . . . ”, Br. J. Pharmacol. (2004), vol. 141, p. 1275-1284.
Zhu, “Discovery of imidazole carboxamides as potent and selective CCK1R agonists”, Bioorg. & Med. Chem. Letters (2008), vol. 18, pp. 4393-4396.
Berger Richard
Edmondson Scott
Hansen Alexa
Zhu Cheng
Bernhardt Emily
Brown Baerbel R.
Merck Sharp & Dohme Corp.
Todaro John C.
LandOfFree
Substituted imidazole 4-carboxamides as cholecystokinin-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted imidazole 4-carboxamides as cholecystokinin-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted imidazole 4-carboxamides as cholecystokinin-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2724008